Study guide
38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers
Philippine Physician Licensure Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: PLE Structure, Eligibility & Study Strategy
1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan
2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle
2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction
3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems
3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments
4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems
4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation
5 Chapter 5: Physiology IV: Neurophysiology & Special Senses
5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses
6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death
6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death
7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning
7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws
8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics
8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics
9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics
9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock
10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection
10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology
11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology
11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura
12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology
12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors
13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry
13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism
14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry
14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure
15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back
15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes
16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin
16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands
17 Chapter 17: Anatomy III: Head, Neck & Histology
17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology
18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections
18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis
19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections
19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning
20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections
20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases
21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections
21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis
22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding
22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage
23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems
23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception
24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception
24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria
25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues
25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents
26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections
26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections
27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders
27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning
28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders
28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child
29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider
29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036
30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine
30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine
31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer
31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health
32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics
32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections
33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics
33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy
34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics
34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis
35 Chapter 35: Surgery I: Basic Surgical Principles
35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety
36 Chapter 36: Surgery II: Abdomen, Breast & Hernia
36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma
37 Chapter 37: Surgery III: Surgical Specialties
37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)
38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine
38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome
39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine
39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS
40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry
40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)
38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers
Key Takeaways Explain This Topic AI
Dyspepsia or reflux with alarm features (age 60 or over by ACG, weight loss, dysphagia, bleeding, anemia, persistent vomiting) needs endoscopy; others get H. pylori test-and-treat or a PPI trial.
Upper GI bleeding in cirrhosis is treated with restrictive transfusion (Hb threshold 7 g/dL), vasoactive drugs, prophylactic ceftriaxone and endoscopy within 12 hours.
Acute pancreatitis needs 2 of 3: typical pain, lipase or amylase more than 3 times normal, and imaging findings; give moderate goal-directed fluids and early oral feeding.
Spontaneous bacterial peritonitis is diagnosed by an ascitic neutrophil count of 250 cells/µL or more and treated with a third-generation cephalosporin plus albumin.
Patients with cirrhosis and many chronic hepatitis B carriers need ultrasound surveillance for hepatocellular carcinoma every 6 months, with or without AFP.
Last updated: October 2026
Why this area matters
The Philippines has a high burden of chronic hepatitis B , which drives cirrhosis and hepatocellular carcinoma , one of the leading causes of cancer death in Filipino men. Infectious diarrhea, typhoid and amebiasis remain common, and peptic ulcer bleeding is a frequent admission. Board questions focus on resuscitation, serology interpretation, and when to scope, refer or operate.
GERD and dyspepsia
GERD:
- heartburn and regurgitation, worse after meals and lying down;
- extraesophageal symptoms : chronic cough, hoarseness, asthma, dental erosions;
- a PPI trial for 8 weeks both diagnoses and treats typical symptoms;
lifestyle : weight loss, raising the head of the bed, avoiding late meals and trigger foods, stopping smoking.
Alarm features needing endoscopy :
- dysphagia or odynophagia;
- weight loss , persistent vomiting;
- GI bleeding or iron deficiency anemia ;
a mass, or onset at an older age (ACG suggests endoscopy for dyspepsia from age 60).
Complications of GERD:
erosive esophagitis and peptic stricture;
Barrett esophagus (intestinal metaplasia), which increases the risk of adenocarcinoma and needs surveillance endoscopy.
Dyspepsia without alarm features: test and treat for H. pylori (urea breath test or stool antigen), or a PPI trial.
Functional dyspepsia is diagnosed after a normal evaluation.
Gastrointestinal Hemorrhage: Triage, Resuscitation & Interventions
Gastrointestinal bleeding is anatomically demarcated by the ligament of Treitz (suspensory muscle of the duodenum) into Upper Gastrointestinal Bleeding (UGIB) and Lower Gastrointestinal Bleeding (LGIB).
Upper Gastrointestinal Bleeding (UGIB)
Clinical Manifestations: Hematemesis (bright red blood or "coffee-ground" emesis), melena (black, tarry, foul-smelling stools resulting from bacterial degradation of hemoglobin over ≥ 14 hours \ge 14\text{ hours} ≥ 14 hours in the gut; requires as little as 50 − 100 mL 50-100\text{ mL} 50 − 100 mL of blood), and occasionally brisk hematochezia (seen in massive, life-threatening UGIB with > 1 , 000 mL > 1,000\text{ mL} > 1 , 000 mL blood loss and hemodynamic instability).
Common Etiologies: Peptic ulcer disease ( 50 % 50\% 50% ), gastroesophageal varices ( 15 − 20 % 15-20\% 15 − 20% ), Mallory-Weiss mucosal lacerations ( 5 − 10 % 5-10\% 5 − 10% , often post-retching), gastroduodenal erosions, Dieulafoy lesions (aberrant submucosal caliber-persistent arteriole), and gastrointestinal malignancies.
Risk Stratification Scores:
Glasgow-Blatchford Score (GBS): Pre-endoscopic risk stratification based on BUN, hemoglobin, systolic blood pressure, pulse, presentation with melena or syncope, and hepatic/cardiac comorbidities. A score of 0 0 0 indicates very low risk, eligible for safe outpatient evaluation.
Rockall Score: Incorporates age, shock, comorbidities, endoscopic findings, and stigmata of recent hemorrhage (active spurting, visible vessel, adherent clot) to predict mortality and rebleeding risk.
Emergency Resuscitation & Pharmacotherapy Protocol:
Airway & Hemodynamic Access: Endotracheal intubation for massive hematemesis, encephalopathy, or severe agitation. Establish two large-bore ( 16 - or 18 -gauge 16\text{- or }18\text{-gauge} 16 - or 18 -gauge ) peripheral IV lines; initiate crystalloid resuscitation.
Restrictive Transfusion Strategy: Transfuse Packed Red Blood Cells (PRBCs) at a hemoglobin threshold of < 7.0 g/dL < 7.0\text{ g/dL} < 7.0 g/dL , targeting a post-transfusion hemoglobin of 7.0 to 8.0 g/dL 7.0\text{ to }8.0\text{ g/dL} 7.0 to 8.0 g/dL . Restrictive transfusion significantly improves survival and reduces rebleeding compared to liberal transfusion ( < 9.0 g/dL < 9.0\text{ g/dL} < 9.0 g/dL ), as excessive volume expansion exacerbates portal venous pressure and clot disruption. (A higher threshold of ≥ 8.0 g/dL \ge 8.0\text{ g/dL} ≥ 8.0 g/dL is reserved for acute coronary syndrome).
High-Dose Intravenous PPI: Administer intravenous Pantoprazole or Esomeprazole ( 80 mg 80\text{ mg} 80 mg IV bolus, followed by 8 mg/hour 8\text{ mg/hour} 8 mg/hour continuous infusion or 40 mg 40\text{ mg} 40 mg IV BID). Raising intragastric pH > 6.0 \text{pH} > 6.0 pH > 6.0 stabilizes fibrin clot formation and suppresses pepsin-mediated clot lysis.
Vasoactive Infusion for Suspected Varices: Initiate Octreotide ( 50 μ g 50\text{ }\mu\text{g} 50 μ g IV bolus, followed by continuous infusion of 50 μ g/hour 50\text{ }\mu\text{g/hour} 50 μ g/hour ) or Terlipressin immediately upon presentation in patients with known or suspected cirrhosis. Octreotide induces selective splanchnic vasoconstriction, reducing portal inflow and variceal pressure.
Short-Course Antibiotic Prophylaxis: In cirrhotic patients presenting with UGIB, administer intravenous Ceftriaxone ( 1 g/day 1\text{ g/day} 1 g/day for up to 7 days) . Prophylactic antibiotics dramatically reduce bacterial infections, spontaneous bacterial peritonitis, early rebleeding, and in-hospital mortality.
Endoscopic Timing & Therapy: Diagnostic and therapeutic esophagogastroduodenoscopy (EGD) should be performed within 24 hours of presentation (within 12 hours for suspected acute variceal hemorrhage following hemodynamic stabilization). Therapeutic modalities include Endoscopic Band Ligation (EBL) for esophageal varices, and dual endoscopic therapy (hemoclips, thermal contact coagulation, or sclerotherapy combined with epinephrine injection) for high-risk bleeding ulcers.
Lower Gastrointestinal Bleeding (LGIB)
Etiology: Arises distal to the ligament of Treitz. Diverticulosis is the most common cause ( 30 − 50 % 30-50\% 30 − 50% , presenting as sudden, painless, large-volume hematochezia), followed by angiodysplasia (vascular ectasia in right colon), ischemic colitis (crampy abdominal pain followed by bloody diarrhea in watershed zones: splenic flexure and rectosigmoid), colorectal polyps/carcinoma, internal hemorrhoids, and inflammatory bowel disease.
Diagnostic Approach: In hemodynamically unstable patients with massive hematochezia, an upper GI source must be excluded first via nasogastric lavage or urgent upper endoscopy. Once stabilized, colonoscopy is the primary diagnostic and therapeutic modality. Active ongoing bleeding can be localized with CT Angiography (detects bleeding rates ≥ 0.3 − 0.5 mL/min \ge 0.3-0.5\text{ mL/min} ≥ 0.3 − 0.5 mL/min ) or Technetium-99m labeled red blood cell scintigraphy (detects rates ≥ 0.1 mL/min \ge 0.1\text{ mL/min} ≥ 0.1 mL/min ).
- Acid-Peptic Disease & Helicobacter pylori
- Gastric versus Duodenal Ulcer Disease
Feature Gastric Ulcer (GU) Duodenal Ulcer (DU)
Peak Age & Demographics Older adults ( 55 − 70 years 55-70\text{ years} 55 − 70 years ) Younger adults ( 30 − 55 years 30-55\text{ years} 30 − 55 years )
Pathophysiology Decreased mucosal defensive barrier; normal or low gastric acid secretion Increased gastric acid secretion; decreased mucosal defense; rapid gastric emptying
Pain Characteristics Pain exacerbated immediately after food ingestion; anorexia, food avoidance, weight loss Pain relieved by food ingestion, recurring 2 − 3 hours 2-3\text{ hours} 2 − 3 hours postprandially; nocturnal pain awakening patient; weight gain common
H. pylori Prevalence 70 % − 80 % 70\% - 80\% 70% − 80% 90 % − 95 % 90\% - 95\% 90% − 95%
Malignancy Risk Higher risk ( 3 − 5 % 3-5\% 3 − 5% represent gastric adenocarcinoma); mandatory biopsy of ulcer margin/base during endoscopy and documentation of endoscopic healing Malignancy is exceedingly rare; routine biopsy of duodenal ulcer base is not mandatory
Anatomic Predilection Lesser curvature of stomach at the incisura angularis First portion of duodenum (duodenal bulb, within 2 cm 2\text{ cm} 2 cm of pylorus)
Helicobacter pylori Eradication Protocols
Helicobacter pylori is a microaerophilic, spiral, flagellated gram-negative rod producing abundant urease, inducing chronic active gastritis and predisposing to peptic ulceration, gastric adenocarcinoma, and MALT lymphoma.
First-Line Regimen in High-Resistance Regions: Bismuth Quadruple Therapy (14 Days) Where clarithromycin resistance exceeds 15 % 15\% 15% or is unknown, bismuth quadruple therapy is the preferred empiric first-line regimen (Maastricht VI; ACG 2024). Philippine resistance data are limited and inconsistent between studies, so local susceptibility should guide therapy:
Proton Pump Inhibitor (PPI): Omeprazole 20 mg 20\text{ mg} 20 mg BID, Esomeprazole 40 mg 40\text{ mg} 40 mg BID, or Lansoprazole 30 mg 30\text{ mg} 30 mg BID.
Bismuth Subsalicylate / Subcitrate: 300 to 524 mg 300\text{ to }524\text{ mg} 300 to 524 mg four times daily (acts as a topical mucosal protectant and antibacterial).
Metronidazole: 500 mg 500\text{ mg} 500 mg three to four times daily.
Tetracycline: 500 mg 500\text{ mg} 500 mg four times daily.
Alternative (Clarithromycin Triple Therapy - 14 Days): PPI BID + Clarithromycin 500 mg 500\text{ mg} 500 mg BID + Amoxicillin 1 , 000 mg 1,000\text{ mg} 1 , 000 mg BID. Used only when local clarithromycin resistance is documented below 15 % 15\% 15% or the strain is known to be susceptible, and in patients without prior macrolide exposure.
Confirmation of Eradication: Must be performed ≥ 4 weeks \ge 4\text{ weeks} ≥ 4 weeks after completion of antibiotic therapy and ≥ 2 weeks \ge 2\text{ weeks} ≥ 2 weeks after stopping PPIs . Non-invasive tests include the Urea Breath Test ( 13 C ^{13}\text{C} 13 C or 14 C ^{14}\text{C} 14 C ) and the Monoclonal Stool Antigen Test . Serum antibody serology remains positive for months to years and cannot be used to prove eradication.
More on bleeding and ulcers:
Variceal bleeding:
- endoscopic band ligation within 12 hours;
- balloon tamponade (Sengstaken-Blakemore) as a temporary bridge;
- TIPS for refractory bleeding;
- secondary prevention : a nonselective beta-blocker (propranolol or carvedilol) plus repeated band ligation;
primary prevention of large varices: a nonselective beta-blocker or band ligation.
Ulcer complications:
perforation : sudden severe pain, a board-like abdomen and free air under the diaphragm, needing surgery;
gastric outlet obstruction : vomiting of undigested food, a succussion splash and hypochloremic hypokalemic metabolic alkalosis .
NSAID ulcers: stop the NSAID; if it must continue, use a PPI or a COX-2 selective drug.
Zollinger-Ellison syndrome (gastrinoma): multiple or distal ulcers with diarrhea, linked to MEN 1 .
Diarrhea and GI infections
Acute diarrhea:
- most cases are viral or toxin-mediated and self-limited;
- assess dehydration and replace losses with oral rehydration solution ;
bloody diarrhea with fever (dysentery) suggests Shigella , Campylobacter , enteroinvasive E. coli or amebiasis ;
rice-water stools with severe dehydration suggest cholera , treated with rapid rehydration and a single dose of doxycycline (or azithromycin);
antibiotics are for dysentery, severe illness, cholera and immunocompromised patients;
avoid antimotility drugs in bloody diarrhea.
Typhoid fever: stepwise fever, relative bradycardia, rose spots and hepatosplenomegaly. Diagnosed by blood culture (bone marrow culture is the most sensitive). Treated with azithromycin , ceftriaxone , or a fluoroquinolone only where isolates are susceptible (fluoroquinolone resistance is widespread in South Asia). Complications are intestinal perforation (third week) and bleeding.
Amebic liver abscess: fever and right upper quadrant pain in men, with an anchovy-paste abscess. Treated with metronidazole followed by a luminal agent (paromomycin or diloxanide).
Chronic diarrhea (more than 4 weeks):
inflammatory bowel disease : ulcerative colitis (continuous from the rectum, bloody diarrhea) and Crohn disease (skip lesions, transmural, fistulas, perianal disease); always exclude intestinal TB in the Philippines before starting steroids or biologics;
irritable bowel syndrome (abdominal pain linked to defecation without alarm features, by the Rome IV criteria);
malabsorption, parasites ( Giardia , Strongyloides , Capillaria in some provinces) and HIV-related infections;
microscopic colitis and colon cancer in older patients.
C. difficile after antibiotics: treated with oral vancomycin or fidaxomicin .
Pancreatitis and biliary disease
Acute pancreatitis:
causes: gallstones and alcohol most commonly, then hypertriglyceridemia (more than 1,000 mg/dL), hypercalcemia, drugs, post-ERCP and trauma;
diagnosis needs 2 of 3 : typical epigastric pain radiating to the back, lipase or amylase more than 3 times the upper limit of normal , and characteristic imaging;
CT is not needed early unless the diagnosis is uncertain or the patient deteriorates after 72 hours;
severity (revised Atlanta): mild (no organ failure), moderately severe (transient organ failure under 48 hours or local complications), severe (persistent organ failure over 48 hours);
treatment : moderate goal-directed fluids with lactated Ringer solution (aggressive fluids cause overload), analgesia, and early oral feeding as tolerated, or enteral rather than parenteral nutrition;
no prophylactic antibiotics ; treat proven infected necrosis, delaying drainage or necrosectomy for about 4 weeks when possible;
ERCP within 24 hours for gallstone pancreatitis with cholangitis ;
cholecystectomy during the same admission for mild gallstone pancreatitis.
Chronic pancreatitis: pain, steatorrhea and diabetes , with calcifications; usually alcohol. Treated with enzymes, analgesia and abstinence.
Acute cholangitis:
- Charcot triad : fever, jaundice and right upper quadrant pain; Reynolds pentad adds shock and confusion;
- treated with IV antibiotics and biliary drainage (ERCP) , urgently in severe cases;
surgical aspects of gallstones and cholecystitis are covered in the surgery chapter.
- Viral Hepatitis & Acute Liver Failure
- Serologic Decoding of Hepatitis B Virus (HBV)
- Clinical Interpretation HBsAg Anti-HBs Anti-HBc IgM Anti-HBc IgG HBeAg Anti-HBe HBV DNA
- Acute Hepatitis B (Early) Positive Negative Positive Negative Positive Negative High
- Window Period Negative Negative Positive Variable Negative Variable Undetectable / Low
- Resolved / Natural Immunity Negative Positive Negative Positive Negative Positive Undetectable
- Vaccine-Induced Immunity Negative Positive Negative Negative Negative Negative Undetectable
Chronic HBV (Active Replication) Positive ( > 6 mo > 6\text{ mo} > 6 mo ) Negative Negative Positive Positive Negative High ( > 20 , 000 IU/mL > 20,000\text{ IU/mL} > 20 , 000 IU/mL )
Chronic HBV (Inactive Carrier) Positive ( > 6 mo > 6\text{ mo} > 6 mo ) Negative Negative Positive Negative Positive Low / Undetectable
Highlights of Other Viral Hepatitides
Hepatitis A (HAV): Fecal-oral transmission; RNA picornavirus. Anti-HAV IgM confirms acute infection. Does not cause chronic hepatitis or carrier state.
Hepatitis C (HCV): Bloodborne/parenteral; single-stranded RNA flavivirus. High chronicity rate ( 75 − 85 % 75-85\% 75 − 85% ). Screening is performed with Anti-HCV; active infection requires confirmation with quantitative HCV RNA PCR. Direct-acting antiviral (DAA) pan-genotypic regimens (Sofosbuvir/Velpatasvir or Glecaprevir/Pibrentasvir) for 8 to 12 weeks achieve sustained virologic response (cure) in > 95 % > 95\% > 95% of patients.
Hepatitis D (HDV): Defective single-stranded circular RNA virus requiring HBsAg coat for assembly. Co-infection (simultaneous acute HBV and HDV) presents like severe acute HBV; Superinfection (acute HDV in a chronic HBsAg carrier) precipitates acute hepatic decompensation or rapid cirrhosis.
Hepatitis E (HEV): Fecal-oral, waterborne. High fatality rate ( 15 % − 25 % 15\% - 25\% 15% − 25% ) in pregnant women due to fulminant hepatic necrosis.
Acute Liver Failure (ALF / Fulminant Hepatic Failure)
Defined by the triad of:
Severe acute liver injury (elevated serum transaminases, jaundice).
Hepatic coagulopathy: International Normalized Ratio (INR) ≥ 1.5 \ge 1.5 ≥ 1.5 .
Any degree of hepatic encephalopathy developing within 26 weeks of initial symptoms in a patient without preexisting cirrhosis .
Etiologies & Specific Antidotes: Acetaminophen toxicity is the most common cause in Western nations (treated with intravenous N-Acetylcysteine ); viral hepatitis is common in developing regions; Amanita phalloides mushroom poisoning (penicillin G and silibinin); Wilson disease (penicillamine, plasma exchange); ischemic hepatitis ("shock liver"). Emergency transfer to a liver transplant center is mandatory.
Cirrhosis & Complications of Portal Hypertension
Cirrhosis is the irreversible end-stage of chronic hepatic injury, defined by diffuse parenchymal bridging fibrosis and regenerative architectural nodule formation.
Ascites & Serum-Ascites Albumin Gradient (SAAG)
Diagnostic abdominal paracentesis must be performed in all patients with new-onset ascites or hospital admission for cirrhotic decompensation. SAAG = Serum Albumin Concentration − Ascitic Fluid Albumin Concentration \text{SAAG} = \text{Serum Albumin Concentration} - \text{Ascitic Fluid Albumin Concentration} SAAG = Serum Albumin Concentration − Ascitic Fluid Albumin Concentration
SAAG Gradient Pathophysiologic Category Etiologies Ascitic Total Protein Diagnostic Utility
High Gradient ( ≥ 1.1 g/dL \ge 1.1\text{ g/dL} ≥ 1.1 g/dL ) Portal Hypertension (increased sinusoidal hydrostatic pressure) Cirrhosis ( 85 % 85\% 85% ) ; Congestive heart failure / Constrictive pericarditis; Budd-Chiari syndrome (hepatic vein thrombosis); Massive hepatic metastases Protein < 2.5 g/dL < 2.5\text{ g/dL} < 2.5 g/dL : Cirrhosis; Protein ≥ 2.5 g/dL \ge 2.5\text{ g/dL} ≥ 2.5 g/dL : Cardiac ascites, early Budd-Chiari
Low Gradient ( < 1.1 g/dL < 1.1\text{ g/dL} < 1.1 g/dL ) Non-Portal Hypertension (altered vascular/peritoneal permeability) Peritoneal Carcinomatosis ; Peritoneal Tuberculosis ; Nephrotic syndrome; Pancreatic or biliary ascites Cytology positive in peritoneal carcinomatosis; Elevated adenosine deaminase (ADA) in peritoneal TB
Medical Management of Cirrhotic Ascites:
Dietary sodium restriction ( < 2 , 000 mg/day < 2,000\text{ mg/day} < 2 , 000 mg/day or 88 mmol/day 88\text{ mmol/day} 88 mmol/day ). Fluid restriction is unnecessary unless serum sodium falls below 125 mEq/L 125\text{ mEq/L} 125 mEq/L .
Dual Diuretic Therapy: Administer oral Spironolactone and Furosemide in a fixed 100:40 mg single daily morning ratio (e.g., 100 mg 100\text{ mg} 100 mg spironolactone with 40 mg 40\text{ mg} 40 mg furosemide, uptitrated together every 3-5 days to maximum 400 mg : 160 mg 400\text{ mg} : 160\text{ mg} 400 mg : 160 mg ). This ratio maintains normokalemia by balancing spironolactone-induced potassium retention with furosemide-induced kaliuresis.
Large-Volume Paracentesis (LVP): Indicated for tense, refractory ascites. When > 5 liters > 5\text{ liters} > 5 liters of ascites is removed, intravenous Albumin ( 6 to 8 g 6\text{ to }8\text{ g} 6 to 8 g per liter of ascites removed) must be infused to prevent Post-Paracentesis Circulatory Dysfunction (PICD), rapid ascites re-accumulation, renal failure, and death.
Spontaneous Bacterial Peritonitis (SBP)
Spontaneous infection of preexisting ascitic fluid without an identifiable surgically treatable intra-abdominal focus, caused by bacterial translocation ( Escherichia coli , Klebsiella pneumoniae , Streptococcus pneumoniae ).
Diagnostic Hallmark: Ascitic fluid Absolute Polymorphonuclear Neutrophil (PMN) Count ≥ 250 cells/ μ L \ge 250\text{ cells/}\mu\text{L} ≥ 250 cells/ μ L (calculated as total leukocyte count × % neutrophils \times \%\text{ neutrophils} × % neutrophils ). A positive culture is not required to initiate therapy.
Therapy: Intravenous third-generation cephalosporin ( Ceftriaxone 2 g 2\text{ g} 2 g IV daily or Cefotaxime 2 g 2\text{ g} 2 g IV q8h) for 5 days.
Renal Protection Protocol: Intravenous Albumin ( 1.5 g/kg 1.5\text{ g/kg} 1.5 g/kg within 6 hours of diagnosis, followed by 1.0 g/kg 1.0\text{ g/kg} 1.0 g/kg on Day 3) significantly decreases the incidence of hepatorenal syndrome and reduces mortality from 29 % 29\% 29% to 10 % 10\% 10% .
Secondary Prophylaxis: Indicated after a single episode of SBP (daily oral Ciprofloxacin 500 mg 500\text{ mg} 500 mg or Trimethoprim-sulfamethoxazole 1 1 1 double-strength tablet daily) indefinitely or until liver transplantation.
Hepatic Encephalopathy (HE)
Neuropsychiatric abnormalities caused by portosystemic shunting and impaired hepatic metabolic clearance of gut-derived neurotoxins, predominantly ammonia ( NH 3 \text{NH}_3 NH 3 ).
Clinical Signs & West Haven Stages: Early sleep reversal, mood alterations, progressed to lethargy, disorientation, asterixis ("liver flap", bilateral flapping tremor of dorsiflexed wrists), somnolence, and coma.
Precipitating Factors: Gastrointestinal bleeding (massive nitrogen load), infection/SBP, hypokalemic metabolic alkalosis (enhances conversion of NH 4 + \text{NH}_4^+ NH 4 + to permeable NH 3 \text{NH}_3 NH 3 ), constipation, excessive dietary protein, sedative medications, and over-diuresis/dehydration.
Treatment:
Identify and correct the precipitating event.
Lactulose (First-Line): Oral synthetic disaccharide degraded by colonic flora into lactic and acetic acids, lowering colonic pH \text{pH} pH . Acidification converts lipophilic diffusible ammonia ( NH 3 \text{NH}_3 NH 3 ) into charged, non-absorbable ammonium ions ( NH 4 + \text{NH}_4^+ NH 4 + ), trapping it in stool ("ammonia trapping"). It also acts as an osmotic cathartic. Titrated to achieve 2 to 3 soft, semi-formed bowel movements per day .
Rifaximin (Second-Line / Add-on): Oral non-absorbable rifamycin antibiotic ( 550 mg 550\text{ mg} 550 mg BID) that eradicates urease-producing gut bacteria, suppressing ammonia synthesis. Added to lactulose for recurrent or refractory encephalopathy.
Hepatorenal Syndrome (HRS)
Extreme functional renal vasoconstriction mediated by intense splanchnic arterial vasodilation in advanced portal hypertension.
Diagnostic Criteria (HRS-AKI): Cirrhosis with ascites; serum creatinine increase ≥ 0.3 mg/dL \ge 0.3\text{ mg/dL} ≥ 0.3 mg/dL in 48 hours or ≥ 50 % \ge 50\% ≥ 50% ; absence of shock; no response after ≥ 48 hours \ge 48\text{ hours} ≥ 48 hours of diuretic withdrawal and volume expansion with IV albumin ( 1 g/kg/day 1\text{ g/kg/day} 1 g/kg/day , maximum 100 g/day 100\text{ g/day} 100 g/day ); absence of proteinuria ( < 500 mg/day < 500\text{ mg/day} < 500 mg/day ) or hematuria ( < 50 RBCs/hpf < 50\text{ RBCs/hpf} < 50 RBCs/hpf ); and normal renal ultrasonography.
Management: Combination of vasoconstrictor therapy (intravenous Terlipressin , or continuous infusion of Norepinephrine , or Octreotide + Midodrine ) PLUS intravenous Albumin ( 20 − 40 g/day 20-40\text{ g/day} 20 − 40 g/day ). Definitive curative therapy is orthotopic liver transplantation.
- Prognostic Scoring Systems in Cirrhosis
- Child-Turcotte-Pugh (CTP) Classification
Evaluates functional hepatic synthetic reserve and perioperative mortality using five parameters (scoring 1 to 3 points each):
- Variable 1 Point 2 Points 3 Points
- Total Bilirubin (mg/dL) < 2.0 < 2.0 < 2.0 2.0 − 3.0 2.0 - 3.0 2.0 − 3.0 > 3.0 > 3.0 > 3.0
- Serum Albumin (g/dL) > 3.5 > 3.5 > 3.5 2.8 − 3.5 2.8 - 3.5 2.8 − 3.5 < 2.8 < 2.8 < 2.8
Prothrombin Time / INR INR < 1.7 \text{INR} < 1.7 INR < 1.7 INR 1.7 − 2.3 \text{INR } 1.7 - 2.3 INR 1.7 − 2.3 INR > 2.3 \text{INR} > 2.3 INR > 2.3
- Ascites None Mild / Diuretic-responsive Moderate to Severe / Refractory
- Hepatic Encephalopathy None Grade 1 - 2 (mild, asterixis) Grade 3 - 4 (severe, coma)
Class A (5 - 6 Points): Well-compensated cirrhosis; 100 % 100\% 100% 1-year survival; perioperative mortality < 10 % < 10\% < 10% .
Class B (7 - 9 Points): Significant functional compromise; 80 % 80\% 80% 1-year survival; perioperative mortality ~30%.
Class C (10 - 15 Points): Decompensated end-stage cirrhosis; 45 % 45\% 45% 1-year survival; perioperative mortality > 75 − 80 % > 75-80\% > 75 − 80% (relative contraindication to elective non-transplant surgery).
Model for End-Stage Liver Disease (MELD-Na)
A continuous objective mathematical score incorporating Bilirubin , INR , Serum Creatinine , and Serum Sodium . Used to prioritize patients for deceased-donor liver transplantation (the United States moved to MELD 3.0, which adds sex and albumin, in 2023) and predicts 90-day mortality.
More on liver disease:
Chronic hepatitis B treatment:
indicated for active hepatitis (raised ALT with high HBV DNA), cirrhosis with any detectable DNA, and some special groups;
tenofovir or entecavir long-term, which suppress the virus and reduce cirrhosis and HCC;
prevention by hepatitis B birth dose vaccination within 24 hours of birth, and HBIG for babies of HBsAg-positive mothers; antivirals in late pregnancy for mothers with high viral loads.
Other chronic liver diseases:
alcohol-associated hepatitis : AST higher than ALT (ratio about 2:1), fever and jaundice; a Maddrey discriminant function of 32 or more suggests steroid treatment;
metabolic dysfunction-associated steatotic liver disease (MASLD) , formerly NAFLD: linked to obesity and diabetes, and now a leading cause of cirrhosis;
Wilson disease (low ceruloplasmin, Kayser-Fleischer rings), hemochromatosis , autoimmune hepatitis, and primary biliary cholangitis (anti-mitochondrial antibodies).
Hepatocellular carcinoma:
- risk factors: hepatitis B (even without cirrhosis), hepatitis C, alcohol, MASLD and aflatoxin ;
- surveillance with ultrasound every 6 months , with or without AFP, in cirrhosis and high-risk HBV carriers;
- diagnosed by arterial enhancement with washout on multiphase CT or MRI (often no biopsy needed);
treated by resection, ablation, transplantation (Milan criteria) , TACE or systemic therapy depending on stage and liver function.
Other GI cancers:
gastric cancer : H. pylori , smoked and salted foods; dyspepsia with weight loss, early satiety, a Virchow node or Sister Mary Joseph nodule;
esophageal cancer : squamous (smoking, alcohol, hot drinks) or adenocarcinoma (Barrett); progressive dysphagia to solids then liquids;
colorectal cancer : screening from age 45 to 50 with FIT or colonoscopy.